A Phase 3 interventional study of Guselkumab Dose 1 and Guselkumab Dose 2 in Colitis, Ulcerative, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 236 sites in 25 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.
Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 8th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2022, is one of 15 in phase 3, reaches primary completion later than 2 of the 20 other live ones, and was the 29th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
Janssen-Cilag Pharma GmbH · Sites in Austria
Ages 18+
Janssen Research & Development, LLC · Sites in United States, Argentina, Australia and 30 more countries
Ages 18+
Janssen-Cilag A.G., Switzerland · Sites in Switzerland
Ages 18+
Xian-Janssen Pharmaceutical Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 18 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 418 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 205 across the 28 interventional studies, 200 across the 15 observational. Of the 22 that completed or were terminated, 9 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
4 of the studies in Colitis, Ulcerative by Johnson & Johnson that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT05092269Phase 3Janssen Research & Development, LLCA Long-term Extension Study of Ustekinumab in Pediatric Participants | 2027-09-29 |
| NCT02808780Janssen Biotech, Inc.An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis | 2026-12-10 |
| NCT07654751Janssen Research & Development, LLCA Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA Therapeutically | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive guselkumab (Dose 1) subcutaneous (SC) injection followed by guselkumab (Dose 2) SC injection.
Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 2
Participants will receive guselkumab (Dose 1) SC injection followed by guselkumab (Dose 3) SC injection.
Drug: Guselkumab Dose 1 · Drug: Guselkumab Dose 3
Participants will receive matching placebo SC injection.
Other: Placebo
Guselkumab (Dose 1) will be administered as SC injection.
Guselkumab (Dose 2) will be administered as SC injection.
Guselkumab (Dose 3) will be administered as SC injection.
Placebo will be administered as SC injection.
Percentage of Participants in Clinical Remission at Week 12
Percentage of participants in clinical remission at Week 12 was reported. Clinical remission is defined as a Mayo stool frequency subscore of 0 or 1 and not increased from baseline, a Mayo rectal bleeding subscore of 0, and a Mayo endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.
Time frame: Week 12
Percentage of Participants in Symptomatic Remission at Week 12
Percentage of participants in symptomatic remission at Week 12 was reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, and a rectal bleeding subscore of 0. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity.
Time frame: Week 12
Percentage of Participants With Endoscopic Improvement at Week 12
Percentage of participants with endoscopic improvement at Week 12 was reported. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.
Time frame: Week 12
Percentage of Participants in Clinical Response at Week 12
Percentage of participants in clinical response at Week 12 was reported. Clinical response is defined as a decrease from baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.
Time frame: Week 12
Percentage of Participants With Histologic-endoscopic Mucosal Improvement at Week 12
Percentage of participants with histologic-endoscopic mucosal improvement at Week 12 was reported. Histologic-endoscopic mucosal improvement is defined as achieving a combination of histologic improvement and endoscopic improvement. Histologic improvement is defined as neutrophil infiltration in less than (\<) 5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.
Time frame: Week 12
Percentage of Participants in Clinical Remission at Week 24
Percentage of participants in clinical remission at Week 24 was reported. Clinical remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, a rectal bleeding subscore of 0, and an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.
Time frame: Week 24
Percentage of Participants in Symptomatic Remission at Week 24
Percentage of participants in symptomatic remission at Week 24 was reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, and a rectal bleeding subscore of 0. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity.
Time frame: Week 24
Percentage of Participants With Endoscopic Improvement at Week 24
Percentage of participants with endoscopic improvement at Week 24 was reported. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.
Time frame: Week 24
Percentage of Participants in Clinical Response at Week 24
Percentage of participants in clinical response at Week 24 was reported. Clinical response is defined as a decrease from baseline in the modified Mayo score by \>= 30% and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.
Time frame: Week 24
Results are currently reported up to the primary completion date (02-Apr-2024). Results of remaining duration will be posted upon study completion.
| Milestone | Placebo | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w |
|---|---|---|---|
| Started | 139 | 139 | 140 |
| Participants who started rescue medication | 52 | 27 | 23 |
| Completed | 131 | 136 | 136 |
| Not completed | 8 | 3 | 4 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 1 | 3 |
| Withdrew: Other | 2 | 2 | 1 |
Percentage of participants in clinical remission at Week 12 was reported. Clinical remission is defined as a Mayo stool frequency subscore of 0 or 1 and not increased from baseline, a Mayo rectal bleeding subscore of 0, and a Mayo endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.
| Percentage of participants | Placebo | Combined Guselkumab 400 mg |
|---|---|---|
| Percentage of Participants in Clinical Remission at Week 12 | 6.5 (2.4 to 10.6) | 27.6 (22.4 to 32.8) |
Percentage of participants in symptomatic remission at Week 12 was reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, and a rectal bleeding subscore of 0. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity.
| Percentage of participants | Placebo | Combined Guselkumab 400 mg |
|---|---|---|
| Percentage of Participants in Symptomatic Remission at Week 12 | 20.9 (14.1 to 27.6) | 51.3 (45.4 to 57.1) |
Percentage of participants with endoscopic improvement at Week 12 was reported. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.
| Percentage of participants | Placebo | Combined Guselkumab 400 mg |
|---|---|---|
| Percentage of Participants With Endoscopic Improvement at Week 12 | 12.9 (7.4 to 18.5) | 37.3 (31.6 to 42.9) |
Percentage of participants in clinical response at Week 12 was reported. Clinical response is defined as a decrease from baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.
| Percentage of participants | Placebo | Combined Guselkumab 400 mg |
|---|---|---|
| Percentage of Participants in Clinical Response at Week 12 | 34.5 (26.6 to 42.4) | 65.6 (60.0 to 71.2) |
Percentage of participants with histologic-endoscopic mucosal improvement at Week 12 was reported. Histologic-endoscopic mucosal improvement is defined as achieving a combination of histologic improvement and endoscopic improvement. Histologic improvement is defined as neutrophil infiltration in less than (\<) 5% of crypts, no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.
| Percentage of participants | Placebo | Combined Guselkumab 400 mg |
|---|---|---|
| Percentage of Participants With Histologic-endoscopic Mucosal Improvement at Week 12 | 10.8 (5.6 to 15.9) | 30.5 (25.1 to 35.9) |
Percentage of participants in clinical remission at Week 24 was reported. Clinical remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, a rectal bleeding subscore of 0, and an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.
| Percentage of participants | Placebo | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w |
|---|---|---|---|
| Percentage of Participants in Clinical Remission at Week 24 | 9.4 (4.5 to 14.2) | 35.3 (27.3 to 43.2) | 36.4 (28.5 to 44.4) |
Percentage of participants in symptomatic remission at Week 24 was reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and not increased from baseline, and a rectal bleeding subscore of 0. Mayo stool frequency subscore was determined on the average number of stools more than normal in 24 hours, score ranged from 0 (normal number of stools) to 3 (5 or more stools more than normal), higher score indicated more severity. Mayo rectal bleeding subscore ranged from 0 (no blood seen) to 3 (blood alone passed), higher score indicated more severity.
| Percentage of participants | Placebo | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w |
|---|---|---|---|
| Percentage of Participants in Symptomatic Remission at Week 24 | 25.2 (18.0 to 32.4) | 54.7 (46.4 to 63.0) | 50.0 (41.7 to 58.3) |
Percentage of participants with endoscopic improvement at Week 24 was reported. Endoscopic improvement is defined as an endoscopy subscore of 0, or 1 with no friability present on the endoscopy. Mayo endoscopy subscore ranged from 0 (normal or inactive disease) to 3 (severe disease), higher score indicated more severity.
| Percentage of participants | Placebo | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w |
|---|---|---|---|
| Percentage of Participants With Endoscopic Improvement at Week 24 | 12.2 (6.8 to 17.7) | 40.3 (32.1 to 48.4) | 45.0 (36.8 to 53.2) |
Percentage of participants in clinical response at Week 24 was reported. Clinical response is defined as a decrease from baseline in the modified Mayo score by \>= 30% and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1. The modified Mayo scores consisted of 3 subscores: stool frequency, rectal bleeding and endoscopic subscore, each subscore graded from 0 (normal) to 3 (severe) with higher scores indicating more severe disease. These individual subscores were summed up to give a total modified Mayo score range of 0 (normal) to 9 (severe disease), where higher scores indicated more severe disease activity.
| Percentage of participants | Placebo | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w |
|---|---|---|---|
| Percentage of Participants in Clinical Response at Week 24 | 30.9 (23.3 to 38.6) | 63.3 (55.3 to 71.3) | 61.4 (53.4 to 69.5) |
Collected over All-cause mortality: From screening (-8 weeks) up to Week 24; Serious adverse events (SAEs) and Other AEs: From Week 0 up to Week 24. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo (Before Rescue Medication) | 1/139 (0.7%) | 17/139 (12.2%) | 48/139 (34.5%) |
| Placebo - Guselkumab (After Rescue Medication) | 0/52 (0%) | 1/52 (1.9%) | 5/52 (9.6%) |
| Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | 0/139 (0%) | 5/139 (3.6%) | 47/139 (33.8%) |
| Guselkumab 400 mg q4w - Guselkumab 200 mg q4w | 0/140 (0%) | 6/140 (4.3%) | 39/140 (27.9%) |
| Event | Placebo (Before Rescue Medication) | Placebo - Guselkumab (After Rescue Medication) | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w |
|---|---|---|---|---|
| Colitis UlcerativeGastrointestinal disorders | 11/139 | 1/52 | 2/139 | 2/140 |
| AnaemiaBlood and lymphatic system disorders | 2/139 | 0/52 | 0/139 | 0/140 |
| AppendicitisInfections and infestations | 0/139 | 0/52 | 0/139 | 2/140 |
| Ventricular ExtrasystolesCardiac disorders | 0/139 | 0/52 | 1/139 | 0/140 |
| Colon DysplasiaGastrointestinal disorders | 1/139 | 0/52 | 0/139 | 0/140 |
| Frequent Bowel MovementsGastrointestinal disorders | 1/139 | 0/52 | 0/139 | 0/140 |
| PyrexiaGeneral disorders | 1/139 | 0/52 | 0/139 | 0/140 |
| GastroenteritisInfections and infestations | 0/139 | 0/52 | 1/139 | 0/140 |
| PneumoniaInfections and infestations | 1/139 | 0/52 | 0/139 | 0/140 |
| Humerus FractureInjury, poisoning and procedural complications | 1/139 | 0/52 | 0/139 | 0/140 |
| Event | Placebo (Before Rescue Medication) | Placebo - Guselkumab (After Rescue Medication) | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w |
|---|---|---|---|---|
| Colitis UlcerativeGastrointestinal disorders | 19/139 | 1/52 | 12/139 | 7/140 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/139 | 0/52 | 11/139 | 7/140 |
| Upper Respiratory Tract InfectionInfections and infestations | 9/139 | 0/52 | 10/139 | 5/140 |
| AnaemiaBlood and lymphatic system disorders | 8/139 | 2/52 | 5/139 | 5/140 |
| NasopharyngitisInfections and infestations | 8/139 | 0/52 | 5/139 | 4/140 |
| HeadacheNervous system disorders | 3/139 | 0/52 | 7/139 | 5/140 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/139 | 0/52 | 6/139 | 2/140 |
| Injection Site ErythemaGeneral disorders | 1/139 | 1/52 | 4/139 | 6/140 |
| Abdominal PainGastrointestinal disorders | 5/139 | 0/52 | 2/139 | 2/140 |
| Covid-19Infections and infestations | 5/139 | 1/52 | 5/139 | 2/140 |
| Age, Continuous(years) | Placebo | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w | Total |
|---|---|---|---|---|
| Mean | 39.5 ± 13.58 | 42.1 ± 14.59 | 43.6 ± 14.27 | 41.7 ± 14.22 |
| Sex: Female, Male(Participants) | Placebo | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w | Total |
|---|---|---|---|---|
| Female | 49 | 60 | 53 | 162 |
| Male | 90 | 79 | 87 | 256 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w | Total |
|---|---|---|---|---|
| Hispanic or Latino | 23 | 30 | 26 | 79 |
| Not Hispanic or Latino | 112 | 102 | 112 | 326 |
| Unknown or Not Reported | 4 | 7 | 2 | 13 |
| Race (NIH/OMB)(Participants) | Placebo | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 4 | 0 | 4 |
| Asian | 40 | 41 | 40 | 121 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 6 | 6 | 13 |
| White | 94 | 85 | 91 | 270 |
| More than one race | 1 | 1 | 1 | 3 |
| Unknown or Not Reported | 3 | 2 | 2 | 7 |
| AgeCategorical(Participants) | Placebo | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w | Total |
|---|---|---|---|---|
| Adults (18-64 years) | 131 | 123 | 131 | 385 |
| 65 years and over | 8 | 16 | 9 | 33 |
| Region of Enrollment(Participants) | Placebo | Guselkumab 400 mg q4w - Guselkumab 100 mg q8w | Guselkumab 400 mg q4w - Guselkumab 200 mg q4w | Total |
|---|---|---|---|---|
| ARGENTINA | 4 | 4 | 3 | 11 |
| AUSTRALIA | 2 | 2 | 3 | 7 |
| BELGIUM | 0 | 2 | 0 | 2 |
| BRAZIL | 17 | 18 | 19 | 54 |
| BULGARIA | 1 | 2 | 1 | 4 |
| CANADA | 1 | 0 | 0 | 1 |
| CHINA | 19 | 12 | 16 | 47 |
| CZECH REPUBLIC | 4 | 5 | 3 | 12 |
| FRANCE | 3 | 6 | 3 | 12 |
| GERMANY | 2 | 1 | 2 | 5 |
| HUNGARY | 3 | 1 | 4 | 8 |
| INDIA | 3 | 2 | 8 | 13 |
| ISRAEL | 2 | 2 | 2 | 6 |
| JAPAN | 7 | 15 | 10 | 32 |
| JORDAN | 9 | 6 | 6 | 21 |
| MALAYSIA | 2 | 3 | 2 | 7 |
| MEXICO | 1 | 5 | 6 | 12 |
| NEW ZEALAND | 3 | 1 | 0 | 4 |
| POLAND | 31 | 28 | 34 | 93 |
| SLOVAKIA | 2 | 0 | 0 | 2 |
| SOUTH KOREA | 7 | 6 | 2 | 15 |
| SPAIN | 5 | 1 | 0 | 6 |
| TAIWAN | 0 | 3 | 1 | 4 |
| TURKEY | 1 | 4 | 2 | 7 |
| UNITED STATES | 10 | 10 | 13 | 33 |
Showing the first 100 of 236 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Sep 2022 to primary completion in Apr 2024, 18 months.
Results were first posted in Dec 2025, 1 year 8 months after primary completion. A results delay was requested in Apr 2025.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 18 months is below that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Guselkumab
Janssen Research & Development, LLC →